MK0782 + aspirin

**MK0782 + aspirin** is an investigational combination of MK0782, a small molecule drug developed by Merck Sharp & Dohme, with **enteric-coated aspirin**. It was studied primarily for evaluating gastrointestinal safety—specifically, the incidence and severity of stomach and duodenal ulcers—when these agents are co-administered, compared to other NSAIDs plus aspirin or placebo. The combination aimed to address pain or inflammatory conditions where aspirin co-therapy is indicated, while assessing the GI side effect profile. The precise mechanism of MK0782 is not published in available sources, but by its trial comparators (rofecoxib, naproxen), it is likely a nonsteroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor.

Other names

MK-0782 + aspirinMK0782 + low-dose aspirin